Alpha-2 agonists in neuroanesthesia

Autor: Victor S.B. Jorden, Alex Bekker
Rok vydání: 2004
Předmět:
Zdroj: Seminars in Anesthesia, Perioperative Medicine and Pain. 23:181-191
ISSN: 0277-0326
DOI: 10.1053/j.sane.2004.01.010
Popis: The primary action of alpha-2 adrenoreceptor agonists is the inhibition of norepinephrine release that causes an attenuation of excitation in the central nervous system (CNS). Activation of these receptors in the CNS produces dose-dependent sedation, anxiolysis, and analgesia (involving spinal and supraspinal sites) without respiratory depression. Alpha-2 agonists have also reduced anesthetic requirements and afford hemodynamic stability during intraoperative period. These clinical characteristics make it a potentially attractive adjunct for neuroanesthesia. When a new drug is introduced into neuroanesthesia practice, however, several considerations must be addressed. A principal concern is a drug’s ability to preserve intracranial homeostasis, to offer a smooth and hemodynamically stable induction, a compatibility with neurophysiologic monitoring, and to assure rapid emergence to a level of consciousness that permits neurologic assessment in the operating room. Additional desirable properties include a reduction of cerebral blood volume, which would minimize brain retraction during the operation, an optimization of oxygen supply/demand relationship, and neuroprotection. This review will discuss pharmacology, current clinical applications, central nervous system effects, and the therapeutic role of clonidine and dexmedetomidine (DEX) (currently available alpha-2 agonists for use in anesthetic practice) in patients undergoing neurosurgical procedures.
Databáze: OpenAIRE